scholarly journals Transient leukopenia after radioactive iodine treatment in patients with Graves’ disease: A retrospective cohort study

2021 ◽  
Author(s):  
Kaoru Yamashita ◽  
Satoshi Morimoto ◽  
Shihori Kimura ◽  
Yasufumi Seki ◽  
Kanako Bokuda ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cohort Study ◽  
Blood Cell ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Bone Marrow Suppression ◽  
Graves Disease ◽  
Long Term Effects ◽  
Cell Counts ◽  
Wbc Count

Abstract Context Radioactive 131I (RAI) for the treatment of differentiated thyroid cancer is known to induce bone marrow suppression, which occurs approximately 1 month post treatment. However, it is unknown whether RAI therapy for Graves’ disease causes bone marrow suppression. Objective This study aimed to evaluate the short- and long-term effects of RAI therapy on bone marrow function in patients with Graves’ disease. Methods In this retrospective cohort study, we included patients with Graves’ disease who received RAI therapy only once between 2003 and 2019 at Tokyo Women’s Medical University. Blood cell counts at baseline were compared with counts at 1, 2, 4, 12, 24, 48, 144, and 240 weeks after RAI therapy. Moreover, changes in white blood cell (WBC) count and leukopenia at 1 week after RAI treatment were compared by baseline patient characteristics. Results We enrolled 48 patients. Leukopenia was observed in 6 patients at 1 week after RAI treatment, and the overall WBC count significantly decreased (p<0.001) 1 week after the therapy; however, the values were not significantly lower after 2 weeks. Neither red blood cell nor platelet count were significantly altered. Moreover, independent of other factors, the neutrophil count at the baseline was significantly negatively associated with changes in WBC count or the occurrence of leukopenia 1 week after the RAI treatment. Conclusions These data showed that RAI treatment induced transient reduction in the WBC count 1 week after treatment, although WBC levels were subsequently restored.

scholarly journals The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals.

2020 ◽  
Author(s):  
Maria Mateos Gonzalez ◽  
Elena Sierra Gonzalo ◽  
Irene Casado Lopez ◽  
Francisco Arnalich Fernandez ◽  
Jose Luis Beato Perez ◽  
...  
Keyword(s):  
Cohort Study ◽  
Blood Cell ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Univariate Analysis ◽  
Cell Depletion ◽  
Complication Rates ◽  
Cell Recovery ◽  
Cell Counts ◽  
Hospitalised Patients

Objectives: A decrease in blood cell counts, especially lymphocytes and eosinophils, has been described in patients with severe SARS-CoV-2 (COVID-19), but there is no knowledge of the potential role of their recovery in these patients prognosis. This article aims to analyse the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Design: This work is a multicentre, retrospective, cohort study of 9,644 hospitalised patients with confirmed COVID-19 from the Spanish Society of Internal Medicine SEMI-COVID-19 Registry. Setting: This study examined patients hospitalised in 147 hospitals throughout Spain. Participants: This work analysed 9,644 patients (57.12% male) out of a cohort of 12,826 patients over 18 years of age hospitalised with COVID-19 in Spain included in the SEMI-COVID-19 Registry as of 29 May 2020. Main outcome measures: The main outcome measure of this work is the effect of blood cell depletion and blood cell recovery on mortality due to COVID-19. Univariate analysis was performed to determine possible predictors of death and then multivariate analysis was carried out to control for potential confounders. Results: An increase in the eosinophil count on the seventh day of hospitalisation was associated with a better prognosis, including lower mortality rates (5.2% vs 22.6% in non-recoverers, OR 0.234 [95% CI, 0.154 to 0.354]) and lower complication rates, especially regarding to development of acute respiratory distress syndrome (8% vs 20.1%, p=0.000) and ICU admission (5.4% vs 10.8%, p=0.000). Lymphocyte recovery was found to have no effect on prognosis. Treatment with inhaled or systemic glucocorticoids was not found to be a confounding factor. Conclusion: Eosinophil recovery in patients with COVID-19 is a reliable marker of a good prognosis that is independent of prior treatment. This finding could be used to guide discharge decisions.

scholarly journals Antithyroid Drug-Induced Hematopoietic Damage: A Retrospective Cohort Study of Agranulocytosis and Pancytopenia Involving 50,385 Patients with Graves' Disease

2012 ◽  
Vol 97 (1) ◽  
pp. E49-E53 ◽  
Author(s):  
Natsuko Watanabe ◽  
Hiroto Narimatsu ◽  
Jaeduk Yoshimura Noh ◽  
Takuhiro Yamaguchi ◽  
Kazuhiko Kobayashi ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Antithyroid Drug ◽  
Graves Disease ◽  
Drug Induced

Safety and Feasibility of Robotic Transaxillary Thyroidectomy for Graves’ Disease: A Retrospective Cohort Study

2022 ◽  
Author(s):  
Mohammed Saad Bu Bshait ◽  
Jin Kyong Kim ◽  
Cho Rok Lee ◽  
Sang-Wook Kang ◽  
Jong Ju Jeong ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Graves Disease ◽  
Transaxillary Thyroidectomy

scholarly journals Occupational radiation and haematopoietic malignancy mortality in the retrospective cohort study of US radiologic technologists, 1983–2012

2020 ◽  
Vol 77 (12) ◽  
pp. 822-831
Author(s):  
Martha S Linet ◽  
Mark P Little ◽  
Cari M Kitahara ◽  
Elizabeth K Cahoon ◽  
Michele M Doody ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cohort Study ◽  
Radiation Dose ◽  
Dose Response ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Radiologic Technologists ◽  
Mortality Risks ◽  
Baseline Questionnaire ◽  
Occupational Radiation

ObjectivesTo evaluate cumulative occupational radiation dose response and haematopoietic malignancy mortality risks in the US radiologic technologist cohort.MethodsAmong 110 297 radiologic technologists (83 655 women, 26 642 men) who completed a baseline questionnaire sometime during 1983–1998, a retrospective cohort study was undertaken to assess cumulative, low-to-moderate occupational radiation dose and haematopoietic malignancy mortality risks during 1983–2012. Cumulative bone marrow dose (mean 8.5 mGy, range 0–430 mGy) was estimated based on 921 134 badge monitoring measurements during 1960–1997, work histories and historical data; 35.4% of estimated doses were based on badge measurements. Poisson regression was used to estimate excess relative risk of haematopoietic cancers per 100 milligray (ERR/100 mGy) bone-marrow absorbed dose, adjusting for attained age, sex and birth year.ResultsDeaths from baseline questionnaire completion through 2012 included 133 myeloid neoplasms, 381 lymphoid neoplasms and 155 leukaemias excluding chronic lymphocytic leukaemia (CLL). Based on a linear dose-response, no significant ERR/100 mGy occurred for acute myeloid leukaemia (ERR=0.0002, 95% CI <−0.02 to 0.24, p-trend>0.5, 85 cases) or leukaemia excluding CLL (ERR=0.05, 95% CI <−0.09 to 0.24, p-trend=0.21, 155 cases). No significant dose-response trends were observed overall for CLL (ERR<−0.023, 95% CI <−0.025 to 0.18, p-trend=0.45, 32 cases), non-Hodgkin lymphoma (ERR=0.03, 95% CI <−0.2 to 0.18, p-trend=0.4, 201 cases) or multiple myeloma (ERR=0.003, 95% CI −0.02 to 0.16, p-trend>0.5, 112 cases). Findings did not differ significantly by demographic factors, smoking or specific radiological procedures performed.ConclusionAfter follow-up averaging 22 years, there was little evidence of a relationship between occupational radiation exposure and myeloid or lymphoid haematopoietic neoplasms.

Sign in / Sign up

Export Citation Format

Share Document